sphingosine-kinase has been researched along with Cardiovascular-Diseases* in 5 studies
4 review(s) available for sphingosine-kinase and Cardiovascular-Diseases
Article | Year |
---|---|
Sphingosine kinase inhibitors: A patent review.
Sphingosine kinases (SphKs) catalyze the conversion of the sphingosine to the promitogenic/migratory product, sphingosine-1-phosphate (S1P). SphK/S1P pathway has been linked to the progression of cancer and various other diseases including allergic inflammatory disease, cardiovascular diseases, rejection after transplantation, the central nervous system, and virus infections. Therefore, SphKs represent potential new targets for developing novel therapeutics for these diseases. The history and development of SphK inhibitors are discussed, summarizing SphK inhibitors by their structures, and describing some applications of SphK inhibitors. We concluded: i) initial SphK inhibitors based on sphingosine have low specificity with several important off-targets. Identification the off-targets that would work synergistically with SphKs, and developing compounds that target the unique C4 domain of SphKs should be the focus of future studies. ii) The modifications of SphK inhibitors, which are devoted to increasing the selectivity to one of the two isoforms, now focus on the alkyl length, the spacer between the head and linker rings, and the insertion and the position of lipidic group in tail region. iii) SphK/S1P signaling pathway holds therapeutic values for many diseases. To find the exact function of each isoform of SphKs increasing the number of SphK inhibitor clinical trials is necessary. Topics: Animals; Cardiovascular Diseases; Drug Discovery; Humans; Hypersensitivity; Lysophospholipids; Molecular Targeted Therapy; Neoplasms; Patents as Topic; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Signal Transduction; Sphingosine | 2018 |
Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances.
Sphingosine kinases (isoforms SK1 and SK2) catalyse the formation of a bioactive lipid, sphingosine 1-phosphate (S1P). S1P is a well-established ligand of a family of five S1P-specific G protein coupled receptors but also has intracellular signalling roles. There is substantial evidence to support a role for sphingosine kinases and S1P in health and disease. This review summarises recent advances in the area in relation to receptor-mediated signalling by S1P and novel intracellular targets of this lipid. New evidence for a role of each sphingosine kinase isoform in cancer, the cardiovascular system, central nervous system, inflammation and diabetes is discussed. There is continued research to develop isoform selective SK inhibitors, summarised here. Analysis of the crystal structure of SK1 with the SK1-selective inhibitor, PF-543, is used to identify residues that could be exploited to improve selectivity in SK inhibitor development for future therapeutic application. Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus; Humans; Inflammation; Lysophospholipids; Models, Molecular; Neoplasms; Neurodegenerative Diseases; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Receptors, G-Protein-Coupled; Signal Transduction; Sphingosine; Structure-Activity Relationship | 2016 |
HDL and its sphingosine-1-phosphate content in cardioprotection.
Increasing evidence suggests that High-density lipoproteins (HDL) are a direct cardioprotective agent in the setting of acute myocardial ischemia/reperfusion injury, and that this cardioprotection occurs independently of their atheroprotective effect. Studies on the involved mechanisms have revealed that the biologically active HDL-compound sphingosine-1-phosphate (S1P) is responsible for the beneficial effect of HDL on the myocardium. There appears to be an intricate interplay between known preconditioning agents and components of the S1P synthesis machinery in the heart, which makes S1P signalling an attractive downstream convergence point of preconditioning and cardioprotection at the level of its G protein-coupled receptors. While local S1P production has been known to protect the heart against ischemia/reperfusion injury and to mediate preconditioning, systemic S1P supply via HDL adds a novel aspect to the regulation of cardioprotection. Thus the S1P-content of HDL may serve both as a potential cardiovascular risk marker and a novel therapeutic target. Strategies for short-term "acute" HDL elevation as well as S1P analogues may prove beneficial not only in the high-risk patient but also in any patient at risk of myocardial ischemia. Topics: Acute Disease; Cardiovascular Diseases; Creatine Kinase; Humans; Ischemic Preconditioning, Myocardial; Lipoproteins, HDL; Lysophospholipids; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Phosphotransferases (Alcohol Group Acceptor); Risk Factors; Signal Transduction; Sphingosine | 2007 |
Point-counterpoint of sphingosine 1-phosphate metabolism.
Sphingosine 1-phosphate (S1P), an evolutionarily conserved bioactive lipid mediator, is now recognized as a potent modulator of cell regulation. In vertebrates, S1P interacts with cell surface G protein-coupled receptors of the EDG family and induces profound effects in a variety of organ systems. Indeed, an S1P receptor agonist is undergoing clinical trials to combat immune-mediated transplant rejection. Recent information on S1P receptor biology suggests potential utility in the control of cardiovascular processes, including angiogenesis, vascular permeability, arteriogenesis, and vasospasm. However, studies from diverse invertebrates, such as yeast, Dictyostelium, Drosophila, and Caenorhabditis elegans have shown that S1P is involved in important regulatory functions in the apparent absence of EDG S1P receptor homologues. Metabolic pathways of S1P synthesis, degradation, and release have recently been described at the molecular level. Genetic and biochemical studies of these enzymes have illuminated the importance of S1P signaling systems both inside and outside of cells. The revelation of receptor-dependent pathways, as well as novel metabolic/intracellular pathways has provided new biological insights and may ultimately pave the way for the development of novel therapeutic approaches for cardiovascular diseases. Topics: Aldehyde-Lyases; Animals; Cardiovascular Diseases; Cardiovascular System; Endothelium, Vascular; Fungi; Humans; Invertebrates; Lysophospholipids; Membrane Proteins; Muscle, Smooth, Vascular; Myocardium; Phosphoric Monoester Hydrolases; Phosphotransferases (Alcohol Group Acceptor); Plants; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Second Messenger Systems; Species Specificity; Sphingosine; Vertebrates | 2004 |
1 other study(ies) available for sphingosine-kinase and Cardiovascular-Diseases
Article | Year |
---|---|
Lipid signalling in cardiovascular pathophysiology.
Topics: Animals; Blood Vessels; Cardiovascular Diseases; Cardiovascular System; Heart; Humans; Lipids; Phosphatidylinositols; Phosphotransferases (Alcohol Group Acceptor); Signal Transduction; Sphingolipids; Sphingomyelin Phosphodiesterase; Sphingosine | 2009 |